Table 1.
Patient demographics and baseline charactersitics (n = 129)
| Characteristics | N (%) |
|---|---|
| Median age (range), years | 63 (34 - 86) |
| Median time from diagnosis to PLD (range), years | 5.9 (0.1 - 26.7) |
| Distribution of metastasis | |
| Bone | 84 (65) |
| Liver | 59 (46) |
| Lymph node | 54 (42) |
| Lung | 48 (37) |
| Skin and sof tissue | 42 (33) |
| Pleura | 30 (23) |
| Abdominal* | 16 (12) |
| Brain | 8 (6) |
| Others+ | 7 (5) |
| Metastatic sites involved | |
| One | 19 (15) |
| Two | 54 (42) |
| Three | 26 (20) |
| Four or more sites | 30 (23) |
| Cardiac risk factors | |
| Prior anthracycline therapy | 77 (60) |
| Age > 60 years | 74 (57) |
| Hypertension | 50 (39) |
| Prior thoracic irradiation† | 39 (30) |
| History of cardiac disease | 35 (27) |
| Median number of cardiac risk factors (range) | 2 (1 - 5) |
| Previous therapies, setting | |
| None | 4 (3) |
| Endocrine, adjuvant | 66 (51) |
| Endocrine, metastatic | 84 (65) |
| Endocrine (adjuvant and/or metastatic) | 95 (74) |
| Chemotherapy, adjuvant | 77 (60) |
| Chemotherapy, metastatic | 99 (77) |
| Chemotherapy (adjuvant and/or metastatic) | 117 (91) |
| Anthracycline containing (adjuvant and/or metastatic) | 77 (60) |
| Taxane containing (adjuvant and/or metastatic) | 73 (57) |
| Trastuzumab-containing (adjuvant/metastatic) | 14 (11) |
| PLD line of chemotherapy‡ | |
| First | 12 (9) |
| Second | 32 (25) |
| Third | 28 (22) |
| Fourth and higher | 57 (44) |
| Median number of PLD cycles (range)§ | 6 (1-6) |
| Median cumulative PLD dose, mg/m2 (range) § | 210 (25 - 300) |
*Including patients with peritoneal, ovarian and intestinal metastasis; +pericardial (n = 3), bone marrow (n = 3) and meningeal involvement (n = 1); †including patients with adjuvant irradiation of the breast; ‡adjuvant chemotherapy was counted as prior therapy line
§PLD cycles within extension therapy (n = 17) not included.